ClinicalTrials.gg
Active, not recruitingNCT05311189Updated Nov 12, 2026

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

A Phase 2 interventional study of HLX10, Trastuzumab and Chemotherapy in HER2-positive Gastric Cancer, sponsored by Shanghai Zhongshan Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Shanghai Zhongshan Hospital · Phase 2, Interventional, and Treatment

How we know · 7 judgments · 2 readings being read again

Updated Nov 12, 2026Now Active, not recruitingFirst site in China+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing serplulimab in Stomach Neoplasms — 8 open to participants now, 11 under way, none of them phase 3. serplulimab · Stomach Neoplasms.

Planned enrollment
12th of 14
40 · median 59
Started
2022
with 2 others
Phase 2
13 of 14
8 open now
Primary completion
2026-12
later than 3 of 10 live
Registered
3rd of 14
by date
Lead sponsor
1 of 14
Shanghai Zhongshan Hospital

Among the 14 studies testing serplulimab in Stomach Neoplasms, this one is the 12th largest by planned enrollment, is one of 3 that started in 2022, is one of 13 in phase 2, reaches primary completion later than 3 of the 10 other live ones, and was the 3rd registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 14 studies testing serplulimab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing serplulimab in Stomach Neoplasms, or all of them as a file.
02

Study summary

Investigators assessed the effectiveness of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

03

Conditions studied

  • HER2-positive Gastric Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤75 years.
  2. score ≥80 within 7 days prior to enrollment.
  3. Newly diagnosed, confirmed, unresectable locally advanced or Her2-positive gastric and gastroesophageal junction adenocarcinoma, able to provide tissue specimens within 1 year for testing (at least 10 unstained slides); positivity defined as IHC3+ or IHC2+ with ISH (or FISH)+ in primary or metastatic tumor lesions. ISH positivity is defined as a HER2 gene copy number to CEP17 signal ratio ≥2.0. If the ratio is \<2.0 but HER2 gene copy number >6, the subject can be considered ISH positive.
  4. Presence of at least one identified during CT/MRI examination according to RECIST1.1 criteria.
  5. Hematology and biochemical parameters of the subjects within 7 days prior to enrollment must meet the following standards:

    1. ≥90 g/L; (ANC) ≥1.5×109/L; ≥100×109/L (patients must not have received blood transfusion or growth factor support within 14 days before blood sample collection);
    2. , AST ≤2.5 times the (ULN); ALP ≤2.5 times ULN;
    3. Total serum \< 1.5 times ULN (patients with Gilbert syndrome can be enrolled if their total bilirubin \< 3 times ULN).
    4. Serum creatinine \< 1.5 times ULN or estimated ≥60 mL/min/1.73m2 (Appendix 3);
    5. Serum albumin ≥30 g/L.
    6. (INR) or prothrombin time (PT) ≤ 1.5 times ULN, unless the patient is receiving anticoagulant therapy and the PT value is within the expected therapeutic range of the anticoagulant.
    7. Activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN.
  6. No serious comorbidities with a \< 5 years.
  7. Able to comply with the protocol during the study.
  8. The patient provides written prior to enrollment in the study, and has been informed of their right to withdraw from the study at any time without any loss.
  9. Women of (Appendix 6) must have a negative urine or serum pregnancy test within 7 days before enrollment and must agree to use effective measures during the study and for at least 120 days after the last dose (including chemotherapy and serplulimab).
  10. Non-sterilized men must agree to use effective contraceptive measures during the study and for at least 120 days after the last dose.

Exclusion criteria

Exclusion criteria

  1. Previous treatment for advanced gastric cancer, including radiotherapy, chemotherapy, and immunotherapy (except for patients who experienced disease recurrence more than 6 months after the end of previous treatment).
  2. Patients with active diseases or a history of autoimmune diseases associated with a possibility of recurrence (Appendix 4).

    Note: Patients with the following diseases are not excluded and can proceed to further screening:

    1. Controlled type 1 diabetes
    2. Hypothyroidism (provided that it can be controlled with hormone replacement therapy alone)
    3. Controlled celiac disease
    4. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia)
    5. Any other diseases that are not expected to recur in the absence of external triggers
  3. Any active within 2 years, except for the specific cancer being studied in this trial and locally recurrent cancers that have been cured (e.g., resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ).
  4. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage within 14 days before enrollment (cytological examination of the effusion is allowed for confirmation).
  5. Gastrointestinal bleeding within 2 weeks before enrollment, or patients judged by the investigator to be at high risk of bleeding.
  6. Gastrointestinal perforation and/or fistula within 6 months before enrollment.
  7. Weight loss ≥20% within 2 months before enrollment.
  8. lung diseases: interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, etc.
  9. Uncontrollable systemic diseases including diabetes mellitus, hypertension, etc.
  10. Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment, including tuberculosis, infection, etc.
  11. Patients with untreated chronic or chronic HBV carriers with HBV DNA exceeding 500 IU/mL, or patients with positive virus (HCV) RNA should be excluded. Non-active hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients (HBV DNA \<500 IU/mL), and cured hepatitis C patients are eligible for inclusion.
  12. Any of the following cardiovascular risk factors:

    1. Cardiogenic chest pain within ≤28 days before enrollment, defined as moderate pain that limits instrumental activities of daily living.
    2. Symptomatic pulmonary embolism within ≤ 28 days before enrollment.
    3. Acute myocardial infarction within ≤ 6 months before enrollment.
    4. Any history of heart failure reaching Class III/IV (Appendix 5) within ≤ 6 months before enrollment.
    5. Grade ≥ 2 ventricular arrhythmia within ≤ 6 months before enrollment, or supraventricular tachyarrhythmia requiring concurrent drug treatment.
    6. Cerebrovascular accident (CVA) within ≤6 months before enrollment.
  13. Known peripheral neuropathy ≥ NCI CTC AE grade 1. However, patients with only the manifestation of absent deep tendon reflexes (DTR) may not be excluded.
  14. Moderate or severe renal impairment [ rate equal to or less than 50 mL/min (calculated according to the Cockroft and Gault equation)], or serum creatinine > (ULN).
  15. Allergic to any components of the study drugs.
  16. Previous stem cell transplantation or organ transplantation.
  17. Patients who required systemic treatment with (at a dose higher than 10 mg/day of prednisone or equivalent dose of similar drugs) or other within ≤ 14 days before enrollment.

    Note: Patients who are currently using or have previously used any of the following steroid regimens are eligible for inclusion:

    1. Adrenal replacement steroids (prednisone ≤10 mg/d or equivalent dose of similar drugs)
    2. Topical, ophthalmic, intra-articular, intranasal, and inhaled corticosteroids with minimal systemic absorption.
    3. Short-term (≤ 7 days) use of corticosteroids for prevention (e.g., for prevention of contrast agent allergy or as an antiemetic for specific chemotherapy) or for treatment of non-autoimmune conditions (e.g., delayed-type reaction caused by contact allergens).
  18. Vaccinated with a within 4 weeks before enrollment. (Note: Seasonal influenza vaccines are usually inactivated vaccines and are permitted for use. Vaccines administered intranasally are live vaccines and are not permitted for use.)
  19. Received immunotherapy (e.g., interleukin, interferon, thymosin, etc.) or any experimental treatment within 28 days or 5 half-lives (whichever is shorter, but at least 14 days) before enrollment.
  20. Received palliative radiotherapy within 14 days before enrollment.
  21. Previously received treatment with , anti-PD-L1, anti-PD-L2, or any other antibodies or drugs specifically targeting T-cell co-stimulation or checkpoint pathways.
  22. Underwent major surgery within 28 days before enrollment, unless the surgery was minimally invasive (e.g., peripherally inserted central catheter [PICC]).
  23. History of uncontrolled epilepsy, central nervous system disease, or mental disorder. The investigator should determine whether its clinical severity prevents the patient from signing the form or affects the patient's compliance with oral medications.
  24. Presence of potential medical conditions, alcohol/drug abuse or dependence that the investigator believes are unfavorable for the administration of the drug or affect the interpretation of drug toxicity or adverse events.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HLX10, Trastuzumab and Chemotherapy

    HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

    Drug: HLX10, Trastuzumab and Chemotherapy

Interventions

  • DrugHLX10, Trastuzumab and Chemotherapy

    Drug pages: SerplulimabBeing read again: the record changed after it was read.Studies of SerplulimabSerplulimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TrastuzumabBeing read again: the record changed after it was read.Studies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients received serplulimab (4.5 mg/kg intravenously on Day 1 every 3 weeks), trastuzumab (an initial loading dose of 8 mg/kg followed by 6 mg/kg intravenously on Day 1 every 3 weeks), docetaxel (40 mg/m² intravenously on Day 1), oxaliplatin (100 mg/m² intravenously on Day 1), and oral S-1 (40-60 mg twice daily based on body surface area on Days 1-14) in 3-week cycles.

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Progression-free survival in patients with HER2-positive gastric cancer receiving HLX10, trastuzumab, and chemotherapy combination treatment

    Time frame: up to 2 years

Secondary outcomes

  1. Overall survival

    Overall survival

    Time frame: Between Day 0 and 3 years

  2. Objective response rate according to RECIST 1.1

    Objective response rate according to RECIST 1.1

    Time frame: Between Day 0, and then every nine weeks up to 2 years of follow-up

  3. Disease Control Rate

    defined as the proportion of patients evaluated as having a CR, PR, or SD at each time point during treatment

    Time frame: up to 2 years

  4. Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE

    Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE

    Time frame: Throughout the overall study period as well as up to 3 months after the last dose study treatment for each subject

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 53 months is close to that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Apr 2022 → Jul 2022, primary completion Dec 2023 → Dec 2026 and completion Dec 2024 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Apr 5, 2022
StartActual
Jul 23, 2022was Apr 2022
Primary completionEst.
Dec 31, 2026was Dec 2023
CompletionEst.
Dec 31, 2027was Dec 2024
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Nov 12, 2026
Sites
1 site added — first site in China
Show site
  • Zhongshan hospital · Shanghai, China
Nov 12, 2026
Start date
Apr 15, 2022→Jul 23, 2022 (actual)
Nov 12, 2026
Primary completion
Dec 31, 2023→Dec 31, 2026
Nov 12, 2026
Study completion
Dec 31, 2024→Dec 31, 2027
Nov 12, 2026
Eligibility
Criteria largely rewritten (76 changes)
What changed in the criteria
Inclusion criteria
  • RemovedHistologically or cytologically proven metastatic or locally advanced HER2-positive gastric cancer
  • RemovedDocumented disease progression after receiving prior line of trastuzumab-containing chemotherapy for gastric cancer
  • RemovedAble and willing to give written informed consent and has signed the informed consent form (ICF), prior to performance of any trial activities.
  • RemovedEligible male and female subjects aged ≥18 years.
  • RemovedHas measurable disease as determined by RECIST 1.1.
  • RemovedEastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • RemovedHas baseline left ventricular ejection fraction (LVEF) ≥ 55%.
  • RemovedAdequate organ function as demonstrated by laboratory test results within 14 days prior to first dose of study treatment.
  • RemovedHave urinary protein that is <2 on dipstick or routine urinalysis.
  • RemovedFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to first dose of study treatment.
  • RemovedFemale subjects of childbearing potential and male subjects should be willing to use methods of birth control for the course of the study and up to 120 days after the last dose of study treatment.
  • AddedAge ≥18 years and ≤75 years.
  • AddedKPS score ≥80 within 7 days prior to enrollment.
  • AddedNewly diagnosed, histologically confirmed, unresectable locally advanced or metastatic Her2-positive gastric and gastroesophageal junction adenocarcinoma, able to provide tissue specimens within 1 year for testing (at least 10 unstained slides); HER2 positivity defined as IHC3+ or IHC2+ with ISH (or FISH)+ in primary or metastatic tumor lesions. ISH positivity is defined as a HER2 gene copy number to CEP17 signal ratio ≥2.0. If the ratio is <2.0 but HER2 gene copy number >6, the subject can be considered ISH positive.
  • AddedPresence of at least one measurable lesion identified during CT/MRI examination according to RECIST1.1 criteria.
  • AddedHematology and biochemical parameters of the subjects within 7 days prior to enrollment must meet the following standards:
  • AddedHemoglobin ≥90 g/L; absolute neutrophil count (ANC) ≥1.5×109/L; platelets ≥100×109/L (patients must not have received blood transfusion or growth factor support within 14 days before blood sample collection);
  • AddedALT, AST ≤2.5 times the upper limit of normal (ULN); ALP ≤2.5 times ULN;
  • AddedTotal serum bilirubin < 1.5 times ULN (patients with Gilbert syndrome can be enrolled if their total bilirubin < 3 times ULN).
  • AddedSerum creatinine < 1.5 times ULN or estimated glomerular filtration rate ≥60 mL/min/1.73m2 (Appendix 3);
  • AddedSerum albumin ≥30 g/L.
  • AddedInternational Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN, unless the patient is receiving anticoagulant therapy and the PT value is within the expected therapeutic range of the anticoagulant.
  • AddedActivated partial thromboplastin time (aPTT) ≤ 1.5 times ULN.
  • AddedNo serious comorbidities with a life expectancy < 5 years.
  • AddedAble to comply with the protocol during the study.
  • AddedThe patient provides written informed consent prior to enrollment in the study, and has been informed of their right to withdraw from the study at any time without any loss.
  • AddedWomen of childbearing potential (Appendix 6) must have a negative urine or serum pregnancy test within 7 days before enrollment and must agree to use effective contraceptive measures during the study and for at least 120 days after the last dose (including chemotherapy and serplulimab).
  • AddedNon-sterilized men must agree to use effective contraceptive measures during the study and for at least 120 days after the last dose.
Exclusion criteria
  • RemovedReceived prior anticancer treatment with targeted agents, chemotherapy, or radiotherapy within 14 days, with monoclonal antibodies within 28 days, has previously received treatment with ramucirumab, or has participated in another clinical trial within 14 days prior to start of study treatment.
  • RemovedHas experienced any Grade 3-4 gastrointestinal bleeding within 3 months prior to treatment.
  • RemovedHas experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 3 months prior to treatment.
  • RemovedHas history of severe thromboembolism, including deep vein thrombosis and pulmonary embolism within 6 months prior to treatment.
  • RemovedHas an active or ongoing infection, symptomatic congestive heart failure, (6)uncontrolled angina pectoris, symptomatic or poorly controlled arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the investigator.
  • Removed(7)Has ongoing or active psychiatric illness or social situation that would limit compliance with study requirements.
  • Removed(8)Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Removed(9)Has evidence of active, non-infectious pneumonitis. (10)Have an elective or a planned major surgery during the course of the trial or has undergone major surgery within 4 weeks prior to enrollment.
  • AddedPrevious treatment for advanced gastric cancer, including radiotherapy, chemotherapy, and immunotherapy (except for patients who experienced disease recurrence more than 6 months after the end of previous adjuvant treatment).
  • AddedPatients with active autoimmune diseases or a history of autoimmune diseases associated with a possibility of recurrence (Appendix 4).
  • AddedNote: Patients with the following diseases are not excluded and can proceed to further screening:
  • AddedControlled type 1 diabetes

…and 36 more changes, on the record history on ClinicalTrials.gov ↗

Nov 12, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameProgression-free survival18 months after start of treatment → up to 2 years
Nov 12, 2026
Secondary outcomes
2 time frame changed, 1 added
What changed in the outcomes
  • AddedDisease Control RateTime frame: up to 2 years
  • Time frameOverall survivalthrough study completion, an average of 2 years → Between Day 0 and 3 years
  • Time frameObjective response rate according to RECIST 1.1through study completion, an average of 2 years → Between Day 0, and then every nine weeks up to 2 years of follow-up
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Status unknown→Active, not recruiting
    1 site added — first site in China
    Show site
    • Zhongshan hospital · Shanghai, China
    Start date Apr 15, 2022→Jul 23, 2022 (now actual)
    Primary completion Dec 31, 2023→Dec 31, 2026
    Study completion Dec 31, 2024→Dec 31, 2027
    Eligibility Criteria largely rewritten (76 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedHistologically or cytologically proven metastatic or locally advanced HER2-positive gastric cancer
    • RemovedDocumented disease progression after receiving prior line of trastuzumab-containing chemotherapy for gastric cancer
    • RemovedAble and willing to give written informed consent and has signed the informed consent form (ICF), prior to performance of any trial activities.
    • RemovedEligible male and female subjects aged ≥18 years.
    • RemovedHas measurable disease as determined by RECIST 1.1.
    • RemovedEastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
    • RemovedHas baseline left ventricular ejection fraction (LVEF) ≥ 55%.
    • RemovedAdequate organ function as demonstrated by laboratory test results within 14 days prior to first dose of study treatment.
    • RemovedHave urinary protein that is <2 on dipstick or routine urinalysis.
    • RemovedFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to first dose of study treatment.
    • RemovedFemale subjects of childbearing potential and male subjects should be willing to use methods of birth control for the course of the study and up to 120 days after the last dose of study treatment.
    • AddedAge ≥18 years and ≤75 years.
    • AddedKPS score ≥80 within 7 days prior to enrollment.
    • AddedNewly diagnosed, histologically confirmed, unresectable locally advanced or metastatic Her2-positive gastric and gastroesophageal junction adenocarcinoma, able to provide tissue specimens within 1 year for testing (at least 10 unstained slides); HER2 positivity defined as IHC3+ or IHC2+ with ISH (or FISH)+ in primary or metastatic tumor lesions. ISH positivity is defined as a HER2 gene copy number to CEP17 signal ratio ≥2.0. If the ratio is <2.0 but HER2 gene copy number >6, the subject can be considered ISH positive.
    • AddedPresence of at least one measurable lesion identified during CT/MRI examination according to RECIST1.1 criteria.
    • AddedHematology and biochemical parameters of the subjects within 7 days prior to enrollment must meet the following standards:
    • AddedHemoglobin ≥90 g/L; absolute neutrophil count (ANC) ≥1.5×109/L; platelets ≥100×109/L (patients must not have received blood transfusion or growth factor support within 14 days before blood sample collection);
    • AddedALT, AST ≤2.5 times the upper limit of normal (ULN); ALP ≤2.5 times ULN;
    • AddedTotal serum bilirubin < 1.5 times ULN (patients with Gilbert syndrome can be enrolled if their total bilirubin < 3 times ULN).
    • AddedSerum creatinine < 1.5 times ULN or estimated glomerular filtration rate ≥60 mL/min/1.73m2 (Appendix 3);
    • AddedSerum albumin ≥30 g/L.
    • AddedInternational Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN, unless the patient is receiving anticoagulant therapy and the PT value is within the expected therapeutic range of the anticoagulant.
    • AddedActivated partial thromboplastin time (aPTT) ≤ 1.5 times ULN.
    • AddedNo serious comorbidities with a life expectancy < 5 years.
    • AddedAble to comply with the protocol during the study.
    • AddedThe patient provides written informed consent prior to enrollment in the study, and has been informed of their right to withdraw from the study at any time without any loss.
    • AddedWomen of childbearing potential (Appendix 6) must have a negative urine or serum pregnancy test within 7 days before enrollment and must agree to use effective contraceptive measures during the study and for at least 120 days after the last dose (including chemotherapy and serplulimab).
    • AddedNon-sterilized men must agree to use effective contraceptive measures during the study and for at least 120 days after the last dose.
    Exclusion criteria
    • RemovedReceived prior anticancer treatment with targeted agents, chemotherapy, or radiotherapy within 14 days, with monoclonal antibodies within 28 days, has previously received treatment with ramucirumab, or has participated in another clinical trial within 14 days prior to start of study treatment.
    • RemovedHas experienced any Grade 3-4 gastrointestinal bleeding within 3 months prior to treatment.
    • RemovedHas experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 3 months prior to treatment.
    • RemovedHas history of severe thromboembolism, including deep vein thrombosis and pulmonary embolism within 6 months prior to treatment.
    • RemovedHas an active or ongoing infection, symptomatic congestive heart failure, (6)uncontrolled angina pectoris, symptomatic or poorly controlled arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the investigator.
    • Removed(7)Has ongoing or active psychiatric illness or social situation that would limit compliance with study requirements.
    • Removed(8)Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
    • Removed(9)Has evidence of active, non-infectious pneumonitis. (10)Have an elective or a planned major surgery during the course of the trial or has undergone major surgery within 4 weeks prior to enrollment.
    • AddedPrevious treatment for advanced gastric cancer, including radiotherapy, chemotherapy, and immunotherapy (except for patients who experienced disease recurrence more than 6 months after the end of previous adjuvant treatment).
    • AddedPatients with active autoimmune diseases or a history of autoimmune diseases associated with a possibility of recurrence (Appendix 4).
    • AddedNote: Patients with the following diseases are not excluded and can proceed to further screening:
    • AddedControlled type 1 diabetes

    …and 36 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameProgression-free survival18 months after start of treatment → up to 2 years
    Secondary outcomes 2 time frame changed, 1 added
    What changed in the outcomes
    • AddedDisease Control RateTime frame: up to 2 years
    • Time frameOverall survivalthrough study completion, an average of 2 years → Between Day 0 and 3 years
    • Time frameObjective response rate according to RECIST 1.1through study completion, an average of 2 years → Between Day 0, and then every nine weeks up to 2 years of follow-up
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05311189
Responsible party
Tianshu Liu (doctor, Shanghai Zhongshan Hospital) — Principal investigator
First posted
Apr 5, 2022
Start date
Jul 23, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Serplulimab · Trastuzumab

Start the discussion